Objectives: Our objective was to determine the feasibility and early to medium-term outcome of stenting the patent ductus arteriosus at the time of radiofrequency valvotomy in the subgroup of patients with pulmonary atresia with intact ventricular septum and intermediate right ventricle.
The wide anatomic spectrum of pulmonary atresia with intact ventricular septum (PAIVS) is widely recognized and thus management strategy needs to be tailored. [1] [2] [3] Patients with membranous atresia and well-developed, ''tripartite'' right ventricle (RV) generally respond well with radiofrequency-assisted valvotomy and balloon dilatation (RFV) or alternatively surgical valvotomy in the neonatal period. This may be the only procedure required (2-ventricle circulation). 4 At the other end of the anatomic spectrum are patients with severe RV hypoplasia, absent infundibulum (muscular atresia), often associated with major RVcoronary communications (sinusoids). This is essentially an anomaly for single-ventricle repair with systemicpulmonary shunt as the initial palliation. 5 Of interest are patients with intermediate anatomy in whom the atresia is membranous and the infundibulum is fairly well developed but the RV is moderately hypoplastic; often the RV is described as ''bipartite.'' At presentation it is unclear whether the RV would ultimately be able to independently support the pulmonary circulation. 6 Although RFV is effective in opening up the pulmonary valve and decompressing the RV, a significant proportion of patients, especially those with moderate RV hypoplasia, require a systemic-pulmonary shunt within days of the procedure. 7, 8 The objectives of this study were to determine the feasibility and safety of concomitant stenting of the patent ductus arteriosus (PDA) at the time of RFV in the subgroup of patients with intermediate RV and, second, to review the medium-term outcome of this subgroup.
METHODS

Definition and Patient Selection
All patients with PAIVS underwent detailed echocardiography and this served as the basis for the initial strategy, which consist mainly of catheter-based therapies. The tricuspid valve (TV) and mitral valve (MV) diameters were measured in diastole. The TV z-score was derived from the normogram by Rowlatt, Rimoldi, and Lev, 9 and TV z-score was calculated. 10 The RV cavity was also described as tripartite, bipartite, or unipartite, depending on the number of parts of the RV (inlet, apical trabecular, and outlet) not obliterated by intracavity muscular overgrowth. Particular attention was paid to whether there was a well-formed infundibulum that ended in a membranous atresia or was obliterated by muscles (muscular atresia). TV regurgitation and its severity, if present, were noted as well as RV-coronary communications. Patients with ''good'' RV are those with a TV z-score of more than À2.5, a TV/MV ratio of 0.75 or more, and membranous atresia with a well-formed infundibulum in which the RV cavity was described as tripartite. The RV volume was not measured quantitatively. 10 Patients with a ''severely diminutive'' RV were defined as those having a TV z-score of less than À5.0, a TV/MV ratio of less than 0.5, and an RV cavity described as unipartite, in which only the inlet component was present and the infundibulum was absent or slitlike. These 2 subgroups were excluded from the study. Also excluded were patients with branch pulmonary artery stenosis, usually the left at the site of ductal insertion. The subjects of this study, termed as having ''intermediate'' RV morphology, were those with a TV z-score ofÀ2.5 toÀ5.0 and/or a TV/MV ratio of 0.50 to 0.75, with the RV described as ''bipartite,'' where apart from the inlet component, a well-formed infundibulum ends in a membranous atresia but the apical trabecular component is absent or attenuated. The decision for recruitment into the study was made by a consensus of 2 of the authors (M.A. and H.S.). Ethics committee approval was obtained.
RFV and PDA Stenting, Postprocedure Care
All patients were subjected to cardiac catheterization under general anesthesia with a view toward catheter-based intervention. Patients with a good RV underwent RFV only. Patients with a severely diminutive (unipartite) RV received PDA stenting only if the PDA was suitable; otherwise, they were referred for systemic-pulmonary shunt. The study patients, those with an intermediate RV, received RFV and concomitant PDA stenting. Prostaglandin E 1 was discontinued the evening before the procedure to ensure the PDA was restrictive. Informed consent was obtained. Baseline hemodynamic data and oxygen saturation were obtained. RV angiogram was performed to delineate the RV cavity, particularly the infundibulum, the valve, and subvalvular area, and to document RV-coronary communications and the possibility of RV-dependent coronary circulation. RV decompression with RFV was not performed in the presence of RVdependent coronary circulation. Aortic arch angiography was performed to delineate the PDA and the pulmonary artery anatomy for the purpose of PDA stenting. RFV and PDA stenting were performed using techniques and equipment as we 4,11 previously described. Coronary stents were used and the sizes chosen were 3.5 mm for patients weighing 2.5 to 2.9 kg, 4.0 mm for those weighing 3.0 to 3.5 kg, and 4.5 mm for those weighing more than 3.5 kg. The stent length was according to that of the PDA. All procedures were done by the transfemoral route. PDA stenting was not performed if branch pulmonary artery stenosis at the site of ductal insertion was shown by angiography. Early in the series, balloon atrial septostomy was also performed if the patent foramen ovale was restrictive, but this was subsequently omitted because we believed that a large interatrial communication would reduce flow to the TV and impair RV growth. After the procedure, the patients were returned to the intensive care unit for continued ventilation and inotropic support as necessary. Heparin infusion was given for 2 days and oral aspirin started the following day and continued until the end point was reached.
Immediate Early Outcome, Follow-up, and Subsequent Procedures
Patients were discharged from the intensive care unit if they could be extubated, could maintain an oxygen saturation greater than 75% in air, and could maintain stable hemodynamics without intropic support. Early reintervention is defined as the patient requiring a systemic-pulmonary shunt within 30 days of the procedure owing to oxygen saturation less than 70% or requiring other surgical/catheter procedures.
After discharge, the patients were reviewed at 1 month, 3 months, and then every 6 months. The degree of cyanosis was assessed clinically. The major tool for evaluation was echocardiography, focusing on the growth of the RV by measuring the TV and MV, and a general assessment of RV cavity, in particular the apical trabecular component. Tricuspid regurgitation, if present, was monitored as well as any residual or recurrence of valvular or subvalvular stenosis. The flow through the ductal stent was noted.
The end points were death before subsequent procedures and, for the surviving patients, attainment of either 2-ventricle circulation or 1½-ventricle circulation. The patients were described as having 2-ventricle circulation and no further treatment was deemed necessary if there was no obvious clinical cyanosis, the echocardiographic evaluation fit the description of tripartite RV with a gradient of 40 mm Hg or less across the RVoutflow tract (RVOT), absent or minimal flow through the PDA, and minimal shunt through the patent foramen ovale. Significant additional problems, if present, such as RVOT obstruction owing to subvalvular muscular overgrowth or hypoplastic pulmonary annulus, shunts through the ASD or PDA, and tricuspid regurgitation were addressed before being categorized as having attained the 2-ventricle circulation.
Patients who remained cyanotic despite good antegrade flow and whose RV growth remained inadequate after 36 to 60 months were subjected to 1½-ventricle circulation by having bidirectional cavopulmonary shunt. Prior cardiac catheterization was performed partly to specifically look for branch left pulmonary artery stenosis as a possible late complication of PDA stenting. At the time of the bidirectional cavopulmonary procedure, the ASD was closed, the PDA stent divided, and additional problems, if present, such as TV regurgitation, RVOT obstruction, pulmonary annular hypoplasia, and branch left pulmonary artery stenosis were addressed accordingly. Patients who had not reached either end point were considered as ''awaiting.''
Analysis of Data
The SPSS statistical program for Windows, version 17.0 (SPSS, Inc, Chicago, Ill), was used for data analysis. Data was expressed as mean AE SD, median (range), and frequency (percentage). Survival and freedom from reinterventions were determined by the Kaplan-Meier method. Reintervention was defined as either catheter-based intervention or surgery.
RESULTS
Between January 2001 and April 2009, 143 patients with PAIVS were referred to our institution. Forty-five patients had good RV (tripartite) and underwent RFV only. The median age at procedure was 10 days (3-65 days) and the mean weight was 3.1 kg (2.6-4.9 kg). The TV z-score was À3.8 AE 2.2. The TV/MV ratio was 0.62 AE 0.16 (Table 1) .
In all patients the RV cavity was described as bipartite, having definite inlet and infundibular components with membranous atresia, whereas the apical trabecular component was severely attenuated. Moderate-to-severe tricuspid regurgitation was present in 12 (32%) patients. Major sinusoids were present in 3 (8.1%), but none had RV-dependent coronary circulation.
The mean procedural time was 111 AE 39 minutes. The median duration of ventilatory support was 1 day (1-15 days). The median length of hospital stay was 8 days (4-23 days) ( Table 1) .
Mortality and Complications
There was no procedural mortality. Two (5%) patients had transient supraventricular tachycardia. One patient had acute stent thrombosis within 24 hours, necessitating systemic-pulmonary shunt. Loss of femoral arterial pulse occurred in 5 (14%) and was successfully treated with heparin and streptokinase.
There were 2 early in-hospital deaths owing to low cardiac output at 10 and 12 days after the procedure. One of these patients had major sinusoids and the other had pulmonary overcirculation. One late death was due to RV failure after RVOT reconstruction surgery. Survival after the initial procedure was 94% at 6 months and remained at 91% from 1 to 4 years ( Figure 1 ).
Follow-up
At a median follow-up of 4 years (6 months to 8.2 years), 8 (23%) patients had not reached the study end point (follow-up <24 months; ie, ''awaiting''). Seventeen (48%) attained biventricular circulation, 8 of whom required reinterventions: transcatheter closure of ASD (n ¼ 2), repeat balloon pulmonary valvuloplasty (n ¼ 1), surgical RVOT reconstruction (n ¼ 4), and PDA restenting and balloon pulmonary valvuloplasty at 3 months, followed by RVOT reconstruction at 14 months (n ¼ 1). Nine (26%) patients did not achieve sufficient RV growth and received bidirectional cavopulmonary shunt, ASD closure, and PDA stent division (1½-ventricle repair), of whom 3 (33%) also received RVOT reconstruction (Figure 1) . No patient had left pulmonary artery stenosis.
The freedom from reintervention was 80%, 68%, 58%, and 40% at 1, 2, 3, and 4 years, respectively (Figure 2 ). However, for those who attained biventricular circulation, the freedom from reintervention was 77%, 70%, 70%, and 61% at 1, 2, 3, and 4 years, respectively ( Figure 3 ). The mean TV score at presentation for those who attained biventricular circulation and 1½-ventricle repair wasÀ2.8 AE 1.8 and À4.1 AE 2.3, respectively.
DISCUSSION
The wide variation of RV morphology in PAIVS has long been recognized and management algorithms have largely been based on this. [1] [2] [3] At one end of the morphologic spectrum are those with a good RV in whom the 3 components of the RV cavity are reasonably well developed-the inlet, apical trabecular, and outlet or infundibulum-even if the RV in general is smaller than that of the normal population. The atresia in this group of patients is membranous in nature. This is the group with the most favorable outcome, comprising 50% to 60% of patients. RV decompression and establishing unobstructed antegrade flow into the pulmonary circulation by surgical valvotomy or RFV in the neonatal period is often the only procedure required, the latter being the favored method of treatment today. 4 At the other end are those with severely diminutive RV with obliteration of the apical trabecular and infundibular cavity. These patients are inevitably destined for the Fontan track. 3, 5, 12 Inasmuch as they are ductus dependent, an initial palliation with systemic-pulmonary shunt is required. PDA stenting, being less invasive, is an attractive alternative to surgical shunt. This is particularly suited to PAIVS, in which the ductus tends to be more amenable to stenting compared with other forms of cyanotic heart disease. 11, 13, 14 This is our preferred mode of initial management.
However, a significant proportion of patients do not exhibit RV features that clearly suggest either the favorable 2-ventricle eventual outcome or the less favorable singleventricle pathway. In our algorithm, this subgroup of patients was designated ''intermediate. ' ' 6 The characteristic features on echocardiography that define this subgroup are TV z-score À2.5 to À5.0, MV/TV ratio 0.5 to 0.75, and an RV cavity that has a severely attenuated apical trabecular component but with a reasonably well-developed infundibulum that ends with a membranous valvular atresia, ''bipartite RV.'' Somewhat out of this continuum of RV morphology are the rare patients with Ebstein anomaly, who have a markedly dilated, thin-walled, poorly functioning RV with severe tricuspid regurgitation. 2 Even today the outlook is very poor, with or without intervention.
Catheter-based therapies have markedly altered the management of PAIVS. RFV is currently the preferred method of initial management, achieving results comparable with if not superior to conventional surgery. 4, 7, 8 The PDA in this condition tends to arise obtusely from the descending aorta to insert onto the dome of the main pulmonary artery rather than onto the proximal left pulmonary artery, making PDA stenting an attractive alternative to systemic-pulmonary shunt. Transcatheter device closure of shunts at ASD or PDA levels can be done as the final procedure. Radical surgery, such as RVOT reconstruction in the neonatal period, is associated with high mortality and morbidity. 12 However, surgery remains an important part of management of PAIVS, especially for those with severely diminutive RV who require the Fontan operation. 5, 12, 15, 16 In patients with intermediate RV that remains incapable of independently supporting the pulmonary circulation, the bidirectional cavopulmonary shunt is an integral part of the 1½-ventricle repair. [17] [18] [19] Although data are currently lacking, we are of the opinion that in the long term the 1½-ventricle circulation is preferable to the Fontan circulation inasmuch as some of the major late complications of the Fontan operation are attributed to the absence of pulsatile flow. This is our basis for this management strategy for those with borderline, ''intermediate'' RV. Surgery may also be additionally required in patients with fixed RVOT obstruction and severe tricuspid regurgitation in both the 2-ventricle and 1½-ventricle pathways.
Less Ideal RV Size and the Basis for ''Prophylactic'' PDA Stenting
The focus of our interest is on the subgroup of patients with borderline or ''intermediate'' RV, one that is difficult to determine at the time of presentation whether it would eventually be capable of sustaining the pulmonary circulation (2-ventricle) or have to be supported by a bidirectional cavopulmonary shunt (1½-ventricle). The initial management of patients with intermediate RV as defined herein is somewhat less clear-cut than those with good tripartite RV or those with severely diminutive RV.
In the surgical era, closed valvotomy or transannular patch with concomitant systemic-pulmonary shunt is a popular management strategy for all patients with patent infundibulum. 20, 21 It was not uncommon for patients to require such a shunt within days of surgical valvotomy alone owing to unacceptably low arterial oxygen tension, hence the concept of ''prophylactic'' systemic-pulmonary shunt at the time of valvotomy. A parallel situation was encountered in the era of transcatheter management with RFV. In a relatively large series of PAIVS patients with seemingly good RV (mean TV z-score À1.33), 14 of 27 patients who successfully underwent RFV required the construction of a systemic-pulmonary shunt 2 to 24 days after the initial procedure. 8 At about the same time, Agnoletti and associates 7 reported that after successful perforation in 33 patients (medium TV z-score À1.2), 12 required a Blalock-Taussig shunt and 8 required a Blalock-Taussig shunt and RVOT reconstruction 1 to 30 days after the initial procedure, with a bias toward those with more negative TV z-score requiring early surgical reintervention. This was also reflected in our own experience, although the proportion of patients who required systemic-pulmonary shunt or PDA stenting within 14 days of RFV was lower. 22 On the basis of these findings, in patients who are identified as having less ideal RV size, that is, the intermediate RV group, there is merit in incorporating PDA stenting into RFV as initial management. The rationale is to avoid reintervention, either systemic-pulmonary shunt or PDA stenting, within days of RFV by maintaining the PDA as an additional source of pulmonary flow until there is sufficient RV ''growth'' (2-ventricle) or otherwise where there is a need then for bidirectional cavopulmonary shunt (1½-ventricle). That PDA stenting in the current era has shown results that are comparable with those of BlalockTaussig shunt in terms of safety and efficacy provides further rationale for this strategy. 11, 13, 14 On the basis of data from these 3 relatively large series and established surgical practice, the argument for concomitant PDA stenting in all patients with PAIVS undergoing RFV does seem persuasive. However, PDA stenting as an alternative to systemic-pulmonary shunt is a newly introduced procedure, it is technically demanding, experience is limited, and the full extent of its late complications is yet to be known. Hence, this treatment strategy cannot be universally recommended for all PAIVS patients, but applying it for a selected group is justifiable.
Our results for this selected group of PAIVS patients showed that this combined procedure was well tolerated and the immediate outcome encouraging as reflected in the intensive care unit stay. There were no deaths or major acute complications owing to the PDA stenting itself, except that in 1 patient acute stent thrombosis developed within 24 hours, requiring emergency systemic-pulmonary shunt.
From our experience, PDA stenting is a reasonable alternative to the Blalock-Taussig shunt in a selected group of patients. However, one needs to be mindful of the possible complications, such as acute stent thrombosis, aggressive neointimal proliferation causing early stent flow restriction, and late branch pulmonary artery stenosis in those in whom the ductus is inserted at the left pulmonary artery. Hence, this has to be excluded at the initial evaluation. 11 In PAIVS, RFV and PDA stenting may cause overcirculation and myocardial ischemia, in particular in those with coronary sinusoids.
In this series, major late complications of PDA stenting were not encountered and a stented PDA did not pose a major surgical challenge at the time of bidirectional cavopulmonary shunt, where the stent was crushed, sutured with 5-0 Prolene polypropylene (Ethicon, Inc, Somerville, NJ), and divided.
As anticipated, not all patients attained 2-ventricle circulation, where normal oxygen saturation is achieved with the RV supporting the entire pulmonary circulation and all shunts abolished. It was also not surprising that 50% of patients who did attain the 2-ventricle end point required reinterventions in the form of RVOT reconstruction, ASD closure, and TV repair given that they started off with less ideal morphology. Twenty-six percent of patients did not achieve sufficient RV ''growth'' after 3.7 years AE 2.9 years and received bidirectional cavopulmonary shunt, ASD closure, and PDA stent division (1½-ventricle repair).
RV ''Growth''
The potential for growth of the RV after decompression and establishment of forward flow is difficult to predict. There have been many published series documenting anatomic growth of the RV, in part contributed by pulmonary regurgitation after valvotomy and regression of muscular hypertrophy after RV decompression. 20, 23, 24 This is also illustrated by 1 of our patients (Figure 4, A-E) . On the other hand, there seem at times, overly optimistic expectations on the capacity for the RV to grow inasmuch as there are also data that showed no significant catch-up anatomic growth of the TV. However, even if there is no catch-up growth, some patients were still able to attain 2-ventricle circulation despite the subnormal RV size. 8, 25 It is thus difficult to determine the size of the RV that will contribute to a successful 2-ventricle circulation. It appears that normal TV growth is not mandatory to have an RV capable of sustaining the pulmonary circulation. ''Physiologic'' growth, that is, improved compliance, is of greater import than anatomic growth. In the face of these uncertainties, RV decompression provides the opportunity for the RV to attain its maximal potential for ''growth,'' both anatomic and physiologic. This can be done less invasively by RFV, and PDA stenting helps support the pulmonary circulation in the interim until either of the end points is reached.
CONCLUSIONS
Concomitant PDA stenting at the time of RFV in PAIVS patients with intermediate RV size is feasible and safe. This treatment strategy largely obviated the need for emergency procedures to augment pulmonary blood flow although acute stent thrombosis may occur in a small percentage.
A quarter of patients with intermediate RV eventually required bidirectional cavopulmonary shunt (1½-ventricle), whereas among those who attained biventricular circulation, a significant proportion required additional procedures. Concomitant with RFV, PDA stenting should be considered an integral part of the initial management in PAIVS with intermediate RV. However, inasmuch as PDA stenting is a relatively new procedure and PAIVS is an uncommon disease, this management strategy warrants wider, multi-institutional study.
